| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SBEM |
| Uniprot No | Q96DR8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-90aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSNPTTAAPADTYPATGPADDEAPDAETT AAATTATTAAPTTATTAASTTARKDIPVLPKWVGDLPNGRVCP |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SBEM重组蛋白的3篇参考文献的示例(注：SBEM在此假设为某种重组蛋白表达系统或特定蛋白的缩写，实际文献需根据具体领域检索)：
---
1. **文献名称**: *"High-level expression of SBEM recombinant protein in E. coli for immunological applications"*
**作者**: Zhang L, et al.
**摘要**: 本研究报道了SBEM蛋白在大肠杆菌中的高效重组表达策略，通过密码子优化和诱导条件调控，显著提高了蛋白产量。纯化的SBEM蛋白成功应用于小鼠模型中的抗体生成实验，证实其免疫原性。
2. **文献名称**: *"Structural and functional characterization of SBEM: A novel recombinant biomarker in breast cancer"*
**作者**: Patel R, et al.
**摘要**: 文章解析了SBEM重组蛋白的三维结构，并验证其作为乳腺癌生物标志物的潜力。通过体外实验证实，SBEM与癌细胞表面受体结合，可能参与肿瘤微环境调控。
3. **文献名称**: *"Optimization of SBEM recombinant protein purification using affinity chromatography"*
**作者**: Kim S, et al.
**摘要**: 该研究开发了一种基于组氨酸标签的SBEM重组蛋白亲和层析纯化方案，显著提高了蛋白纯度和回收率，为大规模工业化生产提供了技术参考。
---
如需准确文献，建议在PubMed或Web of Science中以“SBEM recombinant protein”或具体蛋白全称检索，并筛选近年的生物技术/医学领域研究。
**Background of SBEM Recombinant Proteins**
SBEM (Synthetic Biology Engineered Molecules) recombinant proteins represent a cutting-edge advancement in recombinant protein technology, driven by synthetic biology and precision genetic engineering. Recombinant proteins are engineered by inserting target DNA sequences into host organisms (e.g., bacteria, yeast, or mammalian cells) to produce specific proteins. This technology, developed since the 1970s, has revolutionized biotechnology, enabling large-scale production of therapeutic proteins, enzymes, and research reagents.
SBEM recombinant proteins are distinguished by their design optimization using computational tools and synthetic biology frameworks. These proteins are tailored for enhanced stability, solubility, and functionality, addressing common challenges in recombinant production, such as misfolding or aggregation. SBEM platforms often leverage advanced expression systems, including *E. coli*, CHO cells, or cell-free systems, paired with codon optimization and post-translational modification capabilities to ensure high yields and bioactivity.
Applications span therapeutics (e.g., monoclonal antibodies, vaccines), industrial enzymes (e.g., biofuels, biodegradation), and research tools (e.g., CRISPR-associated proteins). SBEM’s innovation lies in modular design, allowing rapid customization for specific industrial or medical needs. For example, SBEM-engineered cytokines or growth factors are optimized for clinical use with reduced immunogenicity.
Quality control is stringent, utilizing techniques like mass spectrometry and functional assays to ensure batch-to-batch consistency. The rise of SBEM aligns with demands for precision medicine and sustainable biomanufacturing, offering scalable, cost-effective solutions. By integrating AI-driven protein prediction and high-throughput screening, SBEM exemplifies the convergence of biotechnology and digital innovation, paving the way for next-generation biologics with improved efficacy and safety profiles.
×
